<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01779557</url>
  </required_header>
  <id_info>
    <org_study_id>HR-PD-2012</org_study_id>
    <secondary_id>ChiCTR-TRC-13003001</secondary_id>
    <nct_id>NCT01779557</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness Evaluation of Two Kinds of Peritoneal Dialysate</brief_title>
  <acronym>SEED</acronym>
  <official_title>The Prospective, Randomized, Parallel, Controlled, Multi-center Clinical Study of Huaren Peritoneal Dialysate and Baxter Peritoneal Dialysate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the effectiveness and safety of Huaren Peritoneal Dialysate and
      Baxter Peritoneal Dialysate, investigate the proper dialysis dose for Chinese CAPD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, randomized, parallel, controlled, multi-center clinical study of
      Huaren Peritoneal Dialysate and Baxter Peritoneal Dialysate.It aims to investigate the proper
      dialysis dose for Chinese CAPD patients.At the same time,it can evaluate the effectiveness
      and safety of Chinese product Huaren Peritoneal Dialysate and peritoneal dialysis product
      Baxter Peritoneal Dialysate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>survival rate</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PD technique survival rate</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimated glomerular filtration rate decline</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nutritional status</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life(SF-36)</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular events</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>increments of dialysis dose</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>medical costs</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dropout rate</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>AE, vital signs, laboratory tests</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>peritonitis</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>quality of products</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>allergy to PD fluids, bags and tubes</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Kidney Failure,Chronic</condition>
  <arm_group>
    <arm_group_label>Huaren peritoneal dialysate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Huaren Peritoneal dialysate CAPD 3-5 times/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baxter Peritoneal Dialysate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Baxter Peritoneal dialysate CAPD 3-5 times/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Huaren Peritoneal Dialysate</intervention_name>
    <description>Huaren Peritoneal dialysate CAPD 3-5 times/d</description>
    <arm_group_label>Huaren peritoneal dialysate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baxter Peritoneal Dialysate</intervention_name>
    <description>Baxter Peritoneal dialysate CAPD 3-5 times/d</description>
    <arm_group_label>Baxter Peritoneal Dialysate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18, male or female

          -  Patients with end stage renal diseases

          -  Dialysis mode: CAPD

          -  Dialysis duration:≥30 days and ≤6 months

          -  Be capable of implementing home dialysis

          -  Diabetic nephropathy, 3ml/min≤ residual renal GFR ≤15ml/min; other renal diseases,
             3ml/min≤ residual renal GFR ≤10ml/min

          -  Sign the written informed consent

        Exclusion Criteria:

          -  Acute renal failure

          -  Planing to receive kidney transplantation in 2 years

          -  Hemodialysis

          -  Exit site infection or tunnel infection

          -  Presenting 2/3 of the following: a. abdominal pain, turbid ascites, with or without
             fever; b. drainage fluid WBC＞100×106/L, neutrophil ratio＞50%; c.culture positive/ Gram
             stain positive in drainage fluid;

          -  Anti-HIV positive

          -  Allergic to components of dialysate

          -  Active, residual malignant tumor, or systemic infection, liver cirrhosis, severe
             congestive heart failure, anemia（Hb&lt;80g/L）,malnutrition（Serum Alb&lt;28g/L）,refractory
             hypertension

          -  Identified peritoneal high transportation by peritoneal equilibration test (PET)

          -  Extreme body shape (height&gt; 185cm or height &lt;145cm), obesity (BMI ≥ 33kg/m2)

          -  Poor compliance

          -  Pregnant or lactating, women of childbearing age do not agree to use effective
             contraceptive measures during the trial

          -  Has a history of alcoholism and drug abuse (defined as illegal drugs)

          -  Any circumstances when patients are believed unsuitable for this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CHEN Xiangmei, yes</last_name>
    <role>Study Director</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ZHOU Jianhui, Doctor</last_name>
      <phone>+86 010 66935462</phone>
      <email>china_pd@126.com</email>
    </contact>
    <contact_backup>
      <last_name>CHEN Xiangmei, Doctor</last_name>
      <phone>+86 010 66935462</phone>
      <email>xmchen301@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.301hospital.com.cn/</url>
    <description>The website of PLA general hospital</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2013</study_first_submitted>
  <study_first_submitted_qc>January 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2013</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Chen Xiangmei</investigator_full_name>
    <investigator_title>Professor, Chief physician, Academician of Chinese Academy of Engineering</investigator_title>
  </responsible_party>
  <keyword>CAPD</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>survival rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dialysis Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

